Acadia Pharmaceuticals Inc. Earnings

Acadia Pharmaceuticals Inc.’s revenue jumped 18.7% since last year same period to $244.32Mn in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -5.89% fall in its revenue since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit jumped 14.69% since last year same period to $18.99Mn in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -86.79% fall in its net profits since last 3-months.

Acadia Pharmaceuticals Inc.’s net profit margin fell -3.38% since last year same period to 7.77% in the Q1 2025. On a quarterly growth basis, Acadia Pharmaceuticals Inc. has generated -85.96% fall in its net profit margins since last 3-months.

Acadia Pharmaceuticals Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 16.63.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.05 - a -77.17% fall from last quarter’s estimates.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) estimates for the current year stand at 0.05.

Acadia Pharmaceuticals Inc.’s earning per share (EPS) jumped 10% since last year same period to 0.11 in the Q1 2025. This indicates that the Acadia Pharmaceuticals Inc. has generated 10% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Acadia Pharmaceuticals Inc.’s return on assets (ROA) stands at 0.06.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Acadia Pharmaceuticals Inc.’s return on equity (ROE) stands at 0.37.